Home › Companies › RELAY THERAPEUTICS INC. › 2024-2025

RELAY THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and RELAY THERAPEUTICS INC.’s Form 8-K, filed 2025-06-06 (Item 5.07 on EDGAR). Page generated 04 October 2026.

4Ballot items
176Asset managers
971Fund votes
2025-06-06Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore RELAY THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by RELAY THERAPEUTICS INC.

These tallies are RELAY THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-06 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

RELAY THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-06
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Alexis Borisy	80,716,409	--	--	43,000,380	18,744,478	Majority: yes
Elect Director: Mark Murcko, Ph.D.	79,505,170	--	--	44,211,619	18,744,478	Majority: yes
Proposal 2. Non-binding advisory vote on executive compensation.	69,745,321	53,852,178	119,290	--	18,744,478	Majority: yes
Proposal 3. Ratification of appointment of independent registered public accounting firm.	142,184,207	163,544	113,516	--	--	Majority: yes

Source: RELAY THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-06 — read the filing on EDGAR.

How asset managers voted at the RELAY THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 176 asset managers that disclosed a RELAY THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To consider and act upon an advisory vote on the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

56% Majority: yes · of votes cast

FOR 56%AGAINST 44%

FOR: 69,745,321AGAINST: 53,852,178

RELAY THERAPEUTICS INC.’s own tally for this item (“Proposal 2. Non-binding advisory vote on executive compensation.”): 69,745,321 for, 53,852,178 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 170,483,872 outstanding shares: 41% for, 32% against (72% of the company cast a for/against vote).

The 175 asset managers below cast 56% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 55%AGAINST 44%

FOR: 55.1%AGAINST: 44.0%ABSTAIN: 0.8%

Largest asset managers voting on “To consider and act upon an advisory vote on the compensation of our named executive officers;” at RELAY THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
SB INVESTMENT ADVISERS (UK) LTD	27,904,963	0	0	For
Point72	0	13,329,121	0	Against
Vanguard	0	12,193,283	0	Against
BlackRock	10,055,198	63,215	0	For
Bellevue Group AG	0	7,377,292	0	Against
State Street	7,219,106	71,049	0	For
JPMorgan	0	6,454,705	0	Against
T. Rowe Price	5,767,791	0	0	For
Casdin Capital, LLC	5,467,195	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,063,533	0	0	For
Fidelity	3,010,194	0	0	For
MUTUAL FUND SERIES TRUST	0	2,682,083	0	Against
Charles Schwab	0	2,132,100	0	Against
Dimensional	0	1,825,185	0	Against
MPM BioImpact LLC	1,770,283	0	0	For
GV Management Company, L.L.C.	1,564,173	0	0	For
Woodline Partners LP	1,498,763	0	0	For
Two Sigma	0	1,227,453	0	Against
Northern Trust	0	1,054,209	0	Against
Kynam Capital Management, LP	0	0	1,031,265	Abstain
Foresite Capital Management IV, LLC	1,000,000	0	0	For
Renaissance	0	766,641	0	Against
Goldman Sachs	0	723,226	0	Against
TFG Asset Management GP Ltd	699,000	0	0	For
American Century	0	625,580	0	Against

Showing the 25 largest of 175 asset managers. See all 175 in the interactive database.

2. To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Alexis Borisy

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD 35%

FOR: 80,716,409WITHHELD: 43,000,380

RELAY THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alexis Borisy”): 80,716,409 for, 43,000,380 withheld, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 170,483,872 outstanding shares: 47.3% for, 25% withheld (73% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (26,041,717 for, 0 against).

FOR 72%ABSTAIN 28%

FOR: 26,041,717 (72.2%)ABSTAIN: 10,030,438 (27.8%)

Largest asset managers voting on “To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stock” at RELAY THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	11,929,791	0	For
BlackRock	3,897,788	0	For
Fidelity	2,868,478	0	For
MUTUAL FUND SERIES TRUST	0	2,682,083	Abstain
JPMorgan	2,503,023	0	For
State Street	5,958	2,485,355	Abstain
T. Rowe Price	2,375,989	0	For
Dimensional	0	1,520,316	Abstain
Charles Schwab	0	1,066,050	Abstain
Goldman Sachs	0	592,807	Abstain
Columbia Threadneedle	365,223	0	For
Equitable	218,828	136,181	For
American Century	0	312,790	Abstain
TIAA	294,765	0	For
Exchange Place Advisors Trust	247,180	0	For
QUANTITATIVE MASTER SERIES LLC	209,651	0	For
Lincoln Financial	9,804	160,894	Abstain
Thrivent	0	162,388	Abstain
Brighthouse	69,286	81,862	Abstain
Prudential/PGIM	130,100	20,080	For
Jackson National	120,026	23,396	For
AIG/SunAmerica	0	134,506	Abstain
Direxion Shares ETF Trust	0	118,964	Abstain
Invesco	99,184	0	For
Federated Hermes	96,570	0	For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

3. To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Mark Murcko, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%WITHHELD 36%

FOR: 79,505,170WITHHELD: 44,211,619

RELAY THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mark Murcko, Ph.D.”): 79,505,170 for, 44,211,619 withheld, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 170,483,872 outstanding shares: 46.6% for, 26% withheld (73% of the company cast a for/withheld vote).

The 56 asset managers below cast 100% of the shares they voted on this item FOR (25,260,483 for, 0 against).

FOR 70%ABSTAIN 30%

FOR: 25,260,483 (70.0%)ABSTAIN: 10,811,672 (30.0%)

Largest asset managers voting on “To elect the two class II directors to our board of directors, to serve until the 2028 annual meeting of stock” at RELAY THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	11,929,791	0	For
BlackRock	0	3,897,788	Abstain
Fidelity	2,720,199	148,279	For
MUTUAL FUND SERIES TRUST	0	2,682,083	Abstain
JPMorgan	2,503,023	0	For
State Street	2,488,432	2,881	For
T. Rowe Price	2,375,989	0	For
Dimensional	0	1,520,316	Abstain
Charles Schwab	1,066,050	0	For
Goldman Sachs	592,807	0	For
Columbia Threadneedle	0	365,223	Abstain
Equitable	26,192	328,817	Abstain
American Century	0	312,790	Abstain
TIAA	294,765	0	For
Exchange Place Advisors Trust	247,180	0	For
QUANTITATIVE MASTER SERIES LLC	0	209,651	Abstain
Lincoln Financial	104,204	66,494	For
Thrivent	0	162,388	Abstain
Brighthouse	69,286	81,862	Abstain
Prudential/PGIM	130,100	20,080	For
Jackson National	120,026	23,396	For
AIG/SunAmerica	0	134,506	Abstain
Direxion Shares ETF Trust	0	118,964	Abstain
Invesco	0	99,184	Abstain
Federated Hermes	96,570	0	For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%

FOR: 142,184,207AGAINST: 163,544

RELAY THERAPEUTICS INC.’s own tally for this item (“Proposal 3. Ratification of appointment of independent registered public accounting firm.”): 142,184,207 for, 163,544 against, per its Form 8-K filed 2025-06-06 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 170,483,872 outstanding shares: 83% for, 0.1% against (83% of the company cast a for/against vote).

The 56 asset managers below cast 99.9% of the shares they voted on this item FOR (36,039,142 for, 98 against).

FOR 99.9%

FOR: 36,039,142 (99.9%)AGAINST: 98 (0.0%)ABSTAIN: 32,915 (0.1%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at RELAY THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	11,929,791	0	0	For
BlackRock	3,897,788	0	0	For
Fidelity	2,868,478	0	0	For
MUTUAL FUND SERIES TRUST	2,682,083	0	0	For
JPMorgan	2,503,023	0	0	For
State Street	2,491,215	98	0	For
T. Rowe Price	2,375,989	0	0	For
Dimensional	1,520,316	0	0	For
Charles Schwab	1,066,050	0	0	For
Goldman Sachs	592,807	0	0	For
Columbia Threadneedle	365,223	0	0	For
Equitable	355,009	0	0	For
American Century	312,790	0	0	For
TIAA	294,765	0	0	For
Exchange Place Advisors Trust	247,180	0	0	For
QUANTITATIVE MASTER SERIES LLC	209,651	0	0	For
Lincoln Financial	170,698	0	0	For
Thrivent	162,388	0	0	For
Brighthouse	118,233	0	32,915	For
Prudential/PGIM	150,180	0	0	For
Jackson National	143,422	0	0	For
AIG/SunAmerica	134,506	0	0	For
Direxion Shares ETF Trust	118,964	0	0	For
Invesco	99,184	0	0	For
Federated Hermes	96,570	0	0	For

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Largest RELAY THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of RELAY THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 170,483,872 shares outstanding at the time of that meeting.

Top RELAY THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	SB INVESTMENT ADVISERS (UK) LTD	16.37%
2	Point72	7.82%
3	Vanguard	7.15%
4	BlackRock	5.94%
5	Bellevue Group AG	4.33%
6	State Street	4.28%
7	JPMorgan	3.79%
8	T. Rowe Price	3.38%
9	Casdin Capital, LLC	3.21%
10	GEODE CAPITAL MANAGEMENT, LLC	1.80%

Reported RELAY THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

RELAY THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Commodore Capital LP	9.97%	13G
BlackRock	8.49%	13F
Vanguard Group	7.10%	13F
Point72	6.35%	13F
State Street	3.03%	13F
JPMorgan Chase	2.88%	13F
T. Rowe Price	2.04%	13F
Norges Bank	1.99%	13F
Geode Capital	1.80%	13F
Millennium Management	1.73%	13F

Percentages above are of 170,483,872 shares outstanding, as reported by RELAY THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RELAY THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At RELAY THERAPEUTICS INC.'s shareholder meeting held 2025-06-06, in the 2024-2025 proxy season, 176 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 971 separate fund positions. On the most widely held item on that ballot — To consider and act upon an advisory vote on the compensation of our named executive officers; — FOR was 56% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RELAY THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-06.

RELAY THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.